Easiest Way to Get Prescribed Mounjaro in 2026: 4 Paths

Disclosure: Some links on this page are affiliate links. If you start care through them, we may earn a commission at no extra cost to you. Non-affiliate options appear first on this page when they're the better fit for you.

The easiest way to get prescribed Mounjaro is a visit with a licensed clinician who treats type 2 diabetes, who then sends the prescription to LillyDirect or your pharmacy. If you already have a diabetes doctor, start there. If you do not, Eli Lilly currently lists two independent diabetes telehealth options with posted visits from $50 to $129 and average first openings within 24 hours. But one fact decides everything else: Mounjaro is FDA-approved for type 2 diabetes, not weight loss. If you have type 2 diabetes, this page shows the shortest honest route. If you do not, Mounjaro is usually the harder brand to chase — and Zepbound may be the easier, cheaper labeled path.

Here's the part almost nobody tells you. There's a second drug called Zepbound. Same active ingredient. Same company. Same six strengths. It is approved for chronic weight management in eligible adults instead of diabetes. Eli Lilly sells the starting 2.5 mg dose for $299 a month through LillyDirect.

So before you book anything, you need to know which of four doors is yours.

Notice something? The $499 number appears twice. It is a useful manufacturer reference price. It is not a universal floor, and it is not proof by itself that a lower price is fake. Insurance, savings programs, device type, dose, and the exact product all matter.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

This page is for you if:

• You have type 2 diabetes, or a doctor just said you might.
• You want a real prescription from a real prescriber.
• You want to know what actually gets approved instead of guessing.
• You want FDA-approved Mounjaro, not something sold under that name.

This page is not for you if:

• You want a website that skips the medical part. There isn't a safe one.
• You're hoping we'll help you get a diagnosis you don't have. We won't. What we will do is show you the legal labeled path to the same active ingredient when that path fits you.
• You're under 18 and planning to use LillyDirect's Mounjaro self-pay offer. Its terms require you to be 18 or older. More on that gap below — it catches people.

→ Check Sesame Care for a Mounjaro evaluation (sponsored affiliate link; an evaluation does not guarantee a prescription)

→ Weight loss, no diabetes? Run Ro's Zepbound coverage check (sponsored affiliate link)

What we actually verified for this page

We're not going to ask you to take our word for it. Here's what we opened, what kind of source it is, and when.

What we did not do: we didn't get a prescription, enroll in every service, test every pharmacy, or check every insurance plan in America. A listing does not mean a clinician must prescribe. A posted price does not mean your final price will be the same. Where that matters, we say so instead of guessing.

One correction to our own page. Until today, this page said there was no direct cash-pay program for Mounjaro. That was true when we last checked in May. It is not true now. Lilly added Mounjaro to LillyDirect. We were wrong, we fixed it, and we've logged it at the bottom of this page.

There is one more correction inside that correction: Lilly's current wording is "starting at $499/month," not "a flat $499 no matter what." The page lists that starting price for all six single-dose pen strengths, but it also says added taxes and fees may apply. That wording now appears everywhere on this page.

The easiest way to get prescribed Mounjaro depends on your diagnosis

Answer capsule: Mounjaro (tirzepatide) is FDA-approved to improve blood sugar in adults and children 10 and older with type 2 diabetes. It is not FDA-approved for weight loss. A state-authorized prescriber can legally prescribe a drug off-label, but LillyDirect's Mounjaro self-pay offer and both Mounjaro Savings Card tiers require a prescription for an approved use that matches the FDA label. Insurance makes its own coverage decision under your plan.

This is the fork in the road. Everything after it is downstream.

Eli Lilly spells it out in its own savings card rules. The first thing you must agree to is that you were prescribed Mounjaro for an approved use consistent with FDA-approved product labeling. That's type 2 diabetes. Not weight loss.

The LillyDirect Mounjaro self-pay terms say the same thing.

So the honest version is this:

• With a type 2 diabetes diagnosis, a clinician can evaluate you for Mounjaro's labeled use. Safety, age, your medical history, your plan rules, and the clinician's judgment still matter.
• Without one, a prescriber may discuss off-label use, but Lilly's Mounjaro self-pay offer and savings card do not fit that use. If your goal is weight loss and you meet Zepbound's label, the cleaner path is usually Zepbound.

The pediatric gap nobody mentions

Here's a detail that can strand real families.

The FDA label covers adults and children age 10 and older with type 2 diabetes. But LillyDirect's Mounjaro self-pay terms require the buyer to be 18 years of age or older.

So a 13-year-old with type 2 diabetes can be inside the FDA-approved age group and outside Lilly's self-pay offer at the same time. If you're a parent in that situation, the starting-at-$499 self-pay path is not available under the current terms. You'll need a pediatric prescriber and an insurance or regular pharmacy path instead. Worth knowing before you build a plan around a price you can't use.

If you don't have type 2 diabetes, read this before you do anything else

You are not stuck. You may just be looking at the wrong brand.

Zepbound contains the same active ingredient as Mounjaro: tirzepatide. Same manufacturer, Eli Lilly. Same six strengths. The difference is what the FDA approved each product to do. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight reduction and long-term weight maintenance in adults with obesity, or adults with overweight plus at least one weight-related condition. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

That difference can be worth a lot of money.

Here's the math that matters, without pretending the starter dose lasts all year. At 2.5 mg, Zepbound's starting price is $200 less for that fill. At 5 mg, it is $100 less. At a qualifying $449 refill, it is $50 less than Mounjaro's starting-at-$499 price. But Zepbound's 2.5 mg dose is a starter dose, not a maintenance dose, and the $449 higher-dose tier has a 45-day refill rule. Miss that window and Lilly lists a regular price of $499 at 7.5 mg or $699 at 10, 12.5, and 15 mg.

And that's before insurance. A Zepbound claim for an FDA-approved weight indication can be judged under that label. A Mounjaro claim written only for weight loss is off-label. Coverage still depends on the exact plan, formulary, prior-authorization rules, and exclusions.

If your goal is losing weight and you don't have diabetes, stop searching for a trick that turns Mounjaro into a weight-loss label. Ask your clinician whether you meet the Zepbound label instead. It is the same active ingredient under the brand built for that job.

Here's our one honest admission, and it's about our own top partner

Ro does not offer Mounjaro. That's not our opinion — it's stated plainly on Ro's own Mounjaro page, which we checked on August 7, 2026. Ro is the provider we send the most readers to. On this specific page, for this specific drug, they're not the answer.

If exact Mounjaro is what you need, Sesame Care is the better affiliate starting point on this page because it has a dedicated Mounjaro evaluation path. HealthTap may be the better non-affiliate deal for some insured readers. We'll show you both in the next section.

But here's why Ro still matters. Ro built its weight-loss program around FDA-approved weight-loss products, including Zepbound. Ro publishes its membership price, offers an insurance concierge, and lets readers run a coverage check. Those services do not guarantee coverage or a prescription, but they fit the person whose real goal is weight loss rather than the Mounjaro name.

Most people who land on this page don't actually need a particular logo on the box. They need a safe, legal path to the treatment that fits their diagnosis and goal. For an eligible weight-loss patient, Zepbound may be the cleaner door.

→ Weight loss is your goal? Check your Zepbound coverage on Ro (sponsored affiliate link) Get started for $39. Ongoing membership is $74 to $149 a month depending on the plan you choose. Medication is separate.

Not the right fit? Our Foundayo vs. Mounjaro comparison covers the newer once-daily pill.

### Your situation changes the answer The right GLP-1 path isn't the same for everyone. It depends on your diagnosis, your state, your insurance and formulary, whether you want an injection or an oral medicine, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool for a route built around your answers. → Find My GLP-1 Path · Free · About 2 minutes · No signup · Up to 9 short questions The tool does not prescribe medication or guarantee coverage.

Why "easiest" is really three different clocks

Answer capsule: Getting prescribed Mounjaro is not one event. It is three separate decisions made by three different parties: a clinician decides if the medicine is right for you, an insurer decides if it will pay, and a pharmacy decides when it can fill it. Speeding up the first clock does nothing if the second one is what's actually stopping you.

This is the reframe that makes the rest of the page make sense. Most articles treat "get prescribed" as one step. It isn't.

Clock 1 — the clinical decision. How fast can a licensed clinician review your history and decide? This is often the fastest clock. Lilly's diabetes telehealth directory says HealthTap and Sesame each have an average first opening within 24 hours. That is a posted average, not a promise for every state or day.

Clock 2 — the coverage decision. Will your plan pay? This is where many people get stuck, and it can run from a quick electronic answer to days or weeks. It is also the clock you can prepare for most before you spend money.

Clock 3 — pharmacy fulfillment. Once it is prescribed and paid for, can the pharmacy fill it? The national tirzepatide shortage was declared resolved, but FDA says patients can still see local supply gaps as medicine moves through the supply chain.

Ask yourself which clock is your problem. Then read the section that fixes it.

• No clinician? → Read "Where to actually get prescribed Mounjaro."
• Worried about insurance? → Read the paperwork section. That's the big one.
• It's the money? → Read the cost section, where the starting-at-$499 number lives.

Where to actually get prescribed Mounjaro

Answer capsule: Your own doctor is usually the cheapest and fastest option if you can get in. If you can't, Eli Lilly publishes its own short list of independent telehealth providers for diabetes. There are two on it as of August 7, 2026: HealthTap and Sesame. Lilly lists self-pay visits from $50 to $129, appointments seven days a week, and an average first opening within 24 hours. A visit is an evaluation, not a prescription guarantee.

Start with your own doctor if you can

We earn nothing by telling you this, and it's still the right advice. If you already see someone who manages your diabetes, they have your A1C history, your medication list, your allergies, and your record of what you've already tried. That's most of the paperwork battle already won.

Say something like this:

"I'd like to know if Mounjaro is right for my type 2 diabetes. What records or labs do you need from me? And if you prescribe it, can it go to LillyDirect or my pharmacy?"

If you can get an appointment soon, take it. Come back to this page for the paperwork checklist and the cost section.

If you can't get in, or you don't have a doctor, keep reading.

The two independent diabetes telehealth providers Eli Lilly lists

This is a stronger signal than a generic roundup because it comes from the manufacturer of Mounjaro. It is not an endorsement of a specific clinician, and Lilly says the providers are independent.

As of August 7, 2026, Lilly's diabetes telehealth directory lists exactly two options.

Source: Eli Lilly's independent diabetes telehealth directory, document code CMAT-28219 05/2026. Verified August 7, 2026. Prices and availability can change.

One live conflict we found: Lilly's directory says HealthTap accepts select Medicaid. HealthTap's own current support page says it does not accept Medicaid. HealthTap also posts two self-pay choices that Lilly's summary does not spell out: $129 pay per visit, or $44 per primary-care visit with a membership that costs $55 for three months or $180 for one year. Medicaid readers should verify eligibility with HealthTap before booking.

Read that insurance row again, because it's the one that can save people money.

Sesame is self-pay only. HealthTap accepts insurance, including Medicare. Lilly posts a $0-to-$30 copay range based on plan, but HealthTap tells patients to verify the live copay before booking. Do not rely on Lilly's select-Medicaid line without checking because HealthTap's own support page currently says it does not accept Medicaid.

So if you're insured, HealthTap may cost you less for the visit than Sesame does. We have no financial relationship with HealthTap. We're telling you anyway, because it's true and because you'd find out eventually.

Sesame's edge is different. Sesame runs a dedicated Mounjaro page, lets you pick from available clinicians, and says its providers can assist with prior-authorization paperwork. "Can assist" is the accurate wording. It does not mean every request is approved, and it does not mean Sesame controls your insurer.

The audit: we checked whether the recommended platforms actually offer a Mounjaro path

We opened each platform's own current page and read what it says about itself. That matters because provider lists go stale.

The finding: Ro is often named in broad GLP-1 lists, but Ro's own page says it does not carry Mounjaro. If exact Mounjaro is your goal, do not pay for Ro expecting that drug to appear after signup.

We're not attacking anyone. Websites go stale. That's exactly why we date everything and re-check monthly.

Cost and commitment, side by side

Provider-stated prices checked August 7, 2026. They can change. Eligibility, taxes, labs, medicine, and extra visits can change the total. No service can promise that a clinician will prescribe or that a plan will approve.

Two things people get burned on, so we'll say them plainly:

The medication is not included in the care prices above, except where a provider clearly says a different program bundles it. The specific branded-med paths compared in this table bill the medicine separately.

Watch the commitment length. WeightWatchers Med+ starts at $49 for the first month, or $25 on its 6- and 12-month plans. After that, its posted monthly rate depends on the commitment. Its 3-, 6-, and 12-month choices make you financially responsible through the term and auto-renew if not canceled. Noom's ongoing $99 rate is billed quarterly. Ro's lowest monthly-equivalent price requires annual prepayment. PlushCare's membership continues after the free first month. If you want one visit and out, a per-visit model like Sesame's may fit better.

→ See which Sesame providers can evaluate you for Mounjaro in your state (sponsored affiliate link) Pick your clinician from the available options. The provider may help with prior authorization. A visit does not guarantee a prescription.

Insured, especially on Medicare? Check HealthTap first — Lilly lists a $0-to-$30 copay range based on plan, and HealthTap says it accepts Medicare. Verify your exact plan before booking. We don't earn a cent from that option, and for some readers it's simply the better deal.

What your prescriber has to put on the form (this is where most people lose)

Answer capsule: Getting a clinician to say yes is only one part. Your insurer may still require prior authorization — its permission before it pays. In four public Mounjaro appeal decisions we reviewed, two people lost because the requested use fell under an obesity-drug exclusion, one involved type 1 diabetes and weak support for off-label use, and one person with type 2 diabetes lost because the file did not include the needed dates and details from earlier drug trials. The cases do not prove that paperwork causes every denial. They do prove that a true diagnosis cannot rescue an incomplete file.

This is the section most pages skip. Stay with us, because it may be the difference between a clean first request and weeks of avoidable back-and-forth.

First, what prior authorization actually is

Prior authorization — people call it "PA" — means your insurance will not pay until the prescriber's office asks permission and shows that you meet the plan's rules. Your office sends a form and supporting records. The plan says yes, no, or asks for more.

Here's the thing: they're not reading your body. They're reading a file. If the file misses a rule or a document, you can get denied even when the diagnosis itself is not in dispute.

The Denial File: four real cases we reviewed

When someone on MassHealth is denied and fights it, Massachusetts can publish the decision. We reviewed four published Mounjaro decisions from the Massachusetts Board of Hearings.

A note on what these are: these are Massachusetts Medicaid decisions under rules that applied to those cases. Your plan's rules can be different. But the decisions show something no marketing page can show — what a payer reads, and the different ways a real request can fail.

The case you should read twice

Case 2405606 involved a man with type 2 diabetes. His A1C was 7.9. The hearing record says the diagnosis was not the real fight.

His prescriber submitted repeated requests for Mounjaro. They did not get through.

The missing piece was not a secret lab number. It was the timeline. The plan wanted proof of earlier therapy with metformin and either Trulicity or Victoza for at least 90 days in a four-month period, including the specific dates of use. The record did not give the plan enough dates, duration, and combination detail.

That's it. Dates and details.

At the hearing, he compared his case with a friend who had been approved quickly. He also talked about being a father and wanting to live longer.

A real type 2 diabetes diagnosis. A file that still did not meet the rule.

That's the whole reason this section exists, and it's the most useful thing we can hand you.

What the payer actually asked for in that case

The decision reproduced the MassHealth rule that applied to that request. Look at how specific it was.

For that policy, the file needed an appropriate diagnosis plus proof of an inadequate response or adverse reaction to required alternatives. One route called for at least 90 days of therapy inside a four-month period, with dates. The policy also barred use with another GLP-1 medicine.

Three days of metformin would not meet a 90-day rule. Ninety days without dates can still be hard to prove. And your prescriber has to follow your plan's current rule, not the Massachusetts rule on this page.

That level of precision is why "my doctor said I'd probably qualify" and "my insurance approved it" are two very different sentences.

The list to bring to your appointment

Write these down before you go. Exact dates are best. If you only remember a season or year, write that down and ask the old office or pharmacy for the exact record.

• Your diagnosis and when you got it.
• Your most recent A1C and the date it was drawn. A1C is the blood test that shows your average blood sugar over about three months.
• Every diabetes drug you've taken. Metformin, Trulicity, Victoza, Byetta, Ozempic, Jardiance, insulin — whatever it was.
• For each one: when you started, when you stopped, how long you took it, the dose if you know it, and why you stopped. "It didn't work" and "it made me sick" may lead to different documentation.
• Whether you took any of them at the same time as another drug. Case 2405606 turned on this kind of detail.
• Any side effect or allergy, and where it is documented.
• Everything else you take, including over-the-counter medicine and supplements.
• Your insurance card, pharmacy, and the phone number on the back of the card.

If your records are with an old doctor, call that office and ask for your medication history. You can also ask your pharmacy for a fill history. One call can prevent avoidable back-and-forth.

Copy this into your notes before the visit

We built this from the fields that mattered in the public decisions. Copy it, fill in what you know, and bring it with you.

MOUNJARO APPOINTMENT SHEET

Type 2 diabetes diagnosis date:
Latest A1C:
Date of latest A1C:

PAST DIABETES MEDICINES
1. Medicine:
   Dose, if known:
   Start date:
   Stop date:
   Total time used:
   Taken with another diabetes medicine? Which one?
   Why stopped: did not work / side effect / allergy / other
   Record source: old doctor / pharmacy / patient memory / other

2. Medicine:
   Dose, if known:
   Start date:
   Stop date:
   Total time used:
   Taken with another diabetes medicine? Which one?
   Why stopped: did not work / side effect / allergy / other
   Record source: old doctor / pharmacy / patient memory / other

Current medicines and supplements:
Allergies or serious past reactions:
Insurance plan:
Member ID:
Pharmacy:

Questions for the office:
- Does my plan require prior authorization?
- What exact rule does my plan use for Mounjaro?
- Do you need old records before you submit?
- Who should I call for the status?

Free: find which path fits before you book

The RX Index's Find My GLP-1 Path asks up to nine short questions about your goal, insurance, budget, state, and treatment preference. It takes about two minutes and does not ask for an email.

It does not create a medical record, write a prior authorization, prescribe medicine, or guarantee coverage. Use the sheet above for your appointment.

→ Start the free Find My GLP-1 Path tool

If you get denied

Denial is not one thing. It can be a safety decision, a benefit exclusion, a formulary rule, a step-therapy rule, or a missing-document problem. The right next step depends on which one you got.

1. Get the written reason. Do not work from a phone summary. Read the exact rule and the exact missing item.
2. Name the kind of denial. Clinical or safety, coverage or benefit exclusion, formulary or step therapy, or documentation.
3. Ask whether the right move is a corrected new PA, a formulary exception, or an appeal. Do not guess. Ask the plan and the prescriber's office.
4. If records are missing, add dates, duration, dose, response, side effects, and where each fact came from.
5. Ask three questions, word for word:

• "Was this denied for a safety reason, a coverage rule, or missing documentation?"
• "What exact plan rule did I fail?"
• "Should the office send a corrected request, request an exception, or file an appeal?"

If your goal is weight loss and the Mounjaro request was denied because you do not have type 2 diabetes, ask whether you meet the Zepbound label and whether your plan treats Zepbound differently.

For the evidence checklist and letter structure, see our GLP-1 medical necessity letter guide. Use the wording from your own denial notice. Do not claim facts you cannot prove.

→ Got your notes? Book a Sesame diabetes visit and bring them (sponsored affiliate link) Sesame says its providers can assist with prior-authorization paperwork. Your plan still makes the decision.

What Mounjaro actually costs in 2026 (and what $499 really means)

Answer capsule: Eli Lilly now offers Mounjaro through LillyDirect at a self-pay price starting at $499 per month for each of the six listed single-dose pen strengths, from 2.5 mg through 15 mg. The page says a prescription is required and added taxes and fees may apply. Eligible people with commercial insurance that covers Mounjaro may pay as little as $25 with the savings card. People with commercial insurance that does not cover it may qualify for a separate card tier as low as $499. The current manufacturer list price is $1,112.16 for a 28-day supply.

The number that changed this year

On August 7, 2026, we checked Lilly's own LillyDirect page. All six single-dose prefilled pen strengths — 2.5, 5, 7.5, 10, 12.5, and 15 mg — are listed at:

Self-pay price: Starting at $499/month. Prescription required. Terms apply. Additional taxes and fees may apply.

This is new. In a November 6, 2025 agreement with the U.S. government, Lilly said Mounjaro would be added to LillyDirect at 50% to 60% off its list price. Lilly's current list price is $1,112.16. A $499 starting price is about 55% below that number.

That agreement helps explain where the offer came from. It is not a third discount you stack on top of LillyDirect.

Why sites can show different list prices

Lilly's current Mounjaro FAQ states a list price of $1,112.16 for a 28-day supply. That is wholesale acquisition cost, not a promise about what a patient pays.

We also found a real technical problem on Lilly's separate pricing page. In plain-text extraction, the sentence currently loads as, "The list price of Mounjaro is ," with the number missing. The date in its data footnote is blank too. A browser or Lilly's FAQ can show the number while an automated text tool misses it.

That does not explain every wrong price on the internet. It does explain why a page that relies only on automated extraction can lose the number completely.

We use $1,112.16 because Lilly's current Mounjaro FAQ states it directly. Treat list price as a reference, not your expected checkout price.

The full cost ladder

The $499 reference, and what it can and cannot tell you

The $499 number now appears in two separate Mounjaro routes:

1. LillyDirect's self-pay offer starts at $499.
2. The non-covered commercial savings-card tier can be as low as $499.

That makes $499 the most useful current manufacturer reference price for a self-pay or non-covered Mounjaro route. It does not make $499 a universal floor. An insured patient may pay less. A different presentation, assistance program, pharmacy claim, or future offer can change the number.

A very low price can still be a warning sign when a seller claims it is authentic brand-name Mounjaro but will not name the pharmacy, will not require a prescription, or will not show the sealed Lilly product. Price is one clue. It is not proof by itself.

The "$25" asterisk nobody prints

Everyone advertises "as little as $25." Here's the part that gets left off.

For a one-month covered fill, the savings card caps its discount at $150.

So do the subtraction. If your insurance responsibility is $175, the maximum $150 card discount can bring it to $25.

But if your responsibility is $300, a $150 maximum discount leaves $150, not $25.

For a one-month fill, you only reach $25 through that card math when the amount before card savings is $175 or less. Your claim can still be affected by plan rules, accumulators, alternate funding programs, taxes, fees, and Lilly's terms.

A few more card details worth having, all from Lilly's terms as of August 7, 2026:

• Covered tier maximum savings: $150 per 1-month fill, $300 per 2-month fill, or $450 per 3-month fill.
• Covered tier annual maximum: $1,950.
• Non-covered tier maximum savings: $647 per 1-month fill.
• Non-covered tier annual maximum: $8,411.
• Maximum use: up to 13 prescription fills per calendar year.
• The current card expires December 31, 2026 unless Lilly changes or extends it.
• You must have commercial drug insurance and be 18 or older. Government program beneficiaries are excluded.
• The prescription must be for an approved use consistent with the FDA label.
• The card only works on the Mounjaro single-dose pen product codes listed in the terms. Other delivery forms do not qualify.

A small piece of math that helps you read the limits: $150 × 13 one-month fills equals the $1,950 covered-tier annual maximum. And $647 × 13 equals the $8,411 non-covered annual maximum. But a covered 2- or 3-month fill has a larger per-fill cap, so the dollar limit and fill limit are both real. Do not assume one makes the other meaningless.

For the full tier-by-tier breakdown, see our Mounjaro Savings Card guide.

The Medicare trap in the fine print

This one is buried in LillyDirect's purchase terms and it has real consequences.

If you're on Medicare Part D and you buy Mounjaro with cash through LillyDirect, you agree that none of that payment counts toward your Medicare Part D true out-of-pocket, or TrOOP, total. The terms also say you will not count the payment toward an insurance deductible or other out-of-pocket requirement.

In 2026, the Part D annual out-of-pocket threshold is $2,100 for covered Part D drugs. Twelve purchases at the starting $499 price would total $5,988 before any added taxes or fees — and the LillyDirect terms say those cash purchases do not move you toward the Part D TrOOP threshold.

So if you're on Medicare: check your Part D plan first. Mounjaro coverage for type 2 diabetes is plan-specific and may require prior authorization. A plan copay that looks worse for one month can still be better across the year if it counts toward the Part D benefit. Call the plan before you choose cash.

What LillyDirect actually is (and how to use it)

LillyDirect is a pharmacy service, not a doctor. It cannot prescribe. You still need a state-authorized prescriber.

Once you have a prescription, here's exactly what Lilly tells prescribers to use:

Send the prescription to LillyDirect Pharmacy NPI: 1912889320 NCPDP: 1574056 1555 S Harding St, Ste 171-B68 Indianapolis, IN 46221

NPI and NCPDP are routing numbers the prescriber's office will recognize.

After LillyDirect receives the prescription, a pharmacy partner contacts you to confirm details, check available savings, show pharmacy choices, and tell you when the medicine is ready for checkout. LillyDirect says it offers free delivery or retail pickup through participating partners and can help with insurance checks and prior-authorization support. That help is not an approval guarantee.

Questions about a LillyDirect order: 1-844-559-3471.

One rule to understand before you use it. The self-pay terms require you to agree that you will not seek reimbursement from an insurance plan and will not count the purchase toward a deductible, out-of-pocket limit, or Medicare Part D TrOOP. For an uninsured person who meets the offer terms, that can be a clean route. For an insured person, it may not be the best whole-year deal.

→ Book a Mounjaro evaluation that can start the LillyDirect path (sponsored affiliate link) LillyDirect cannot write the prescription. Sesame visits on Lilly's directory run $50 to $100. A clinician must decide that Mounjaro is appropriate for an approved use.

What your first month can cost, all in

We calculated the starting visit-plus-medicine total using the posted care price and LillyDirect's starting-at-$499 medicine price. This is not a quote.

Estimated first-month totals based on public prices checked August 7, 2026. Assumes a clinician prescribes Mounjaro for an approved use and sends it to LillyDirect. Excludes taxes, LillyDirect fees, lab charges, follow-up visits, and later membership charges. The HealthTap member route includes its three-month membership charge in the starting cash outlay. HealthTap insurance cost depends on the plan.

Notice the HealthTap rows. Its quarterly-member route can start below the $129 pay-per-visit route, while an insured visit can be cheaper still. But a LillyDirect cash drug purchase will not count toward insurance. Compare the first cash outlay and the full year before choosing.

How fast can this actually happen?

Answer capsule: A telehealth appointment may be available within 24 hours, and a prescription can be written the same day when the clinician has enough information and decides Mounjaro is appropriate. Filling it is a separate question. If your plan requires prior authorization, add time for the plan to review it. If the first file is incomplete, add more.

Clock 1, the visit. Lilly's diabetes directory says HealthTap and Sesame each average a first opening within 24 hours. That is a posted average, not a guarantee. Your own doctor may be faster or slower.

Clock 2, the coverage decision. This is the wild card. An electronic decision can come back quickly, but a fast denial is still a denial. Case 2405606 shows repeated requests can fail when the new submission still does not add the missing detail.

Standard prior-authorization timing varies by plan and plan type. Ask your insurer directly:

"What is your standard turnaround for a Mounjaro prior authorization, what makes a request eligible for expedited review, and where can I check the status?"

Get it in the plan's words, not ours.

Clock 3, the pharmacy. LillyDirect says its pharmacy partner will contact you after it receives the prescription and tell you when the medicine is ready for checkout. A local pharmacy may fill it the same day if the claim clears and the dose is in stock. Local supply can still vary even though the national shortage is resolved.

The single biggest time-saver is not always a faster provider. It is knowing which clock is slow and walking in with the records that clock needs. A complete file cannot guarantee approval. It can prevent a denial caused by a blank line.

Shortcuts that don't work, and one that's dangerous

Answer capsule: The broad shortage-based lane for pharmacies to make copies of tirzepatide ended in 2025 after FDA declared the shortage resolved. A narrow patient-specific compounding route can still exist under section 503A when a prescriber documents a change that creates a significant difference for that identified patient. Compounded tirzepatide is not FDA-approved and is not Mounjaro. A website that skips licensed screening and a prescription is not an easier Mounjaro path.

Compounded tirzepatide: what actually happened

Compounding means a pharmacy makes a medicine for a patient instead of dispensing the finished FDA-approved product. During the national shortage, FDA used temporary enforcement discretion that allowed much broader production of tirzepatide copies. That window closed.

A narrow lane still exists under 503A. It requires an individual prescription, and the prescriber must document why the change creates a significant difference for that patient when the product would otherwise count as an essentially copied drug. Wanting to pay less, by itself, is not the patient-specific clinical difference described in FDA's rule.

Some sellers add vitamin B12 and call the result personalized. In a March 12, 2026 open letter, Eli Lilly said its own testing found an impurity created when tirzepatide was mixed with B12 and said the effects of that impurity in people are unknown. Compounders publicly disputed Lilly's conclusions. This is a manufacturer finding and a live dispute, not an FDA finding.

What isn't disputed: compounded drugs are not FDA-approved. They do not go through FDA's premarket review for safety, effectiveness, or quality. Compounded tirzepatide is not Mounjaro, and no one should tell you it is.

FDA also says that, as of May 31, 2026, it had received more than 730 adverse-event reports associated with compounded tirzepatide. FDA says reporting is incomplete and it is not always possible to tell whether the compounded drug caused the event. That number is a safety signal, not proof that every compounded product caused harm.

The no-prescription sites

Red flags, in plain terms:

• No screening and no prescription from a licensed prescriber. FDA lists this as a telehealth warning sign.
• The seller says its compounded drug is "the same as" Mounjaro. It is not the FDA-approved Lilly product.
• The price or claim sounds too good to be true. Price alone is not proof, but deep discounts plus hidden sourcing are a bad mix.
• "Research use only" or "not for human consumption" labeling. FDA warns consumers not to buy these products for use in people.
• No real prescriber or licensed clinician available after the sale. You need someone who can answer safety and dosing questions.
• A missing, false, or misspelled pharmacy name or address. FDA has found fraudulent compounded GLP-1 labels that name pharmacies that did not make the product.
• Broken packaging, no instructions, a product that looks different from what was promised, or an injectable that arrives warm when it should be refrigerated. Do not use it. Contact the dispensing pharmacy and your clinician.
• You choose any dose you want without a clinician. Real care follows a dosing plan and checks the medicines you already take.

Illegal online tirzepatide may be counterfeit or may contain too little, too much, no active ingredient, or a harmful ingredient. That does not mean every unfamiliar package is counterfeit. It means you should verify the prescriber, pharmacy, label, and product before using it.

How to check a pharmacy in two minutes, using FDA's own guidance: a safe online pharmacy requires a prescription, lists a U.S. address and phone number, has a licensed pharmacist you can reach, and is licensed by a state board of pharmacy. Check the license with the board in the state where the pharmacy is located. If you cannot confirm it, walk away.

Asking for Mounjaro when you mean Zepbound

We'll say it one more time because it is an easy delay to cause yourself in this category. If you do not have type 2 diabetes and your goal is weight loss, asking for Mounjaro puts you on an off-label path and outside Lilly's Mounjaro self-pay and savings-card terms. Ask whether you meet Zepbound's label instead.

What we won't help with

Some pages in this space hint at how to phrase things so a prescriber writes something that isn't quite accurate. We're not going to do that, and any site that does isn't protecting you — it's exposing you.

Your clinician's evaluation isn't red tape. Tirzepatide carries a boxed warning, has real contraindications and warnings, and can raise the risk of low blood sugar when used with insulin or a sulfonylurea. The evaluation is the part that checks whether this fits your body and your other medicine.

The good news is you do not need a workaround. If you want tirzepatide for weight loss and meet the label, Zepbound is the legal FDA-approved brand built for that use.

Who shouldn't take Mounjaro?

Answer capsule: Mounjaro carries a boxed warning about thyroid C-cell tumors seen in rats. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, and anyone who has had a serious allergic reaction to tirzepatide or a Mounjaro ingredient. Type 1 diabetes is outside Mounjaro's approved use, but it is not listed as a formal contraindication in the current label.

A boxed warning is the strongest warning FDA requires on a prescription-drug label. For Mounjaro, the human risk of thyroid C-cell tumors is unknown. The warning exists because tirzepatide caused these tumors in rats.

Do not use Mounjaro if:

• You or a family member has had medullary thyroid carcinoma, or MTC, a specific type of thyroid cancer.
• You have Multiple Endocrine Neoplasia syndrome type 2, or MEN 2, an inherited condition that affects hormone glands.
• You've had a serious allergic reaction to tirzepatide or any Mounjaro ingredient.

Mounjaro is not FDA-approved for type 1 diabetes. That is different from saying type 1 diabetes is a formal contraindication. Appeal 2309642 above involved type 1 diabetes and an off-label request that did not meet the payer's evidence rule.

Your clinician will also weigh:

• A history of pancreatitis.
• Gallbladder disease.
• Kidney problems or dehydration risk.
• Diabetic eye disease or past diabetic retinopathy complications.
• Severe stomach problems, including severe gastroparesis. The label says Mounjaro is not recommended in severe gastroparesis.
• Pregnancy, plans to become pregnant, or breastfeeding.
• Insulin or a sulfonylurea, because the combination can raise the risk of low blood sugar.
• A planned surgery or procedure with anesthesia or deep sedation, because GLP-1 drugs delay stomach emptying and rare aspiration events have been reported.

One more the label calls out: oral birth-control pills may work less well after you start Mounjaro and after a dose increase. The label tells patients who use oral hormonal contraception to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. Ask your clinician what fits you.

If a clinician says no because of a real safety concern, that isn't the system failing you. That's the system working. Ask what would fit better — there are other options, and a good clinician will point you to one.

Read the full Mounjaro prescribing information and the Medication Guide that comes with the medicine.

What if my doctor won't prescribe Mounjaro?

Answer capsule: Ask why before you go looking for a different prescriber. The answer may be a safety concern, a missing record, the clinician's medical judgment, or a coverage rule. A second opinion is reasonable. Shopping until someone says yes without looking at your history is not.

If it's a safety reason — a contraindication, a serious interaction risk, severe stomach disease, pregnancy concern, or something else in your history — listen. Ask the clinician to explain the risk and the safer choices.

If it's a documentation reason, it may be fixable. Get the old records, lab dates, and medication history. Come back with the file.

If it's a coverage reason, you have a few real moves:

A formulary is your plan's list of covered drugs. Step therapy means the plan asks you to try a preferred option before it pays for another one.

When a specialist helps. If your diabetes has been hard to control, your history is complicated, or your primary care clinician suggests it, an endocrinologist may be the better person to sort through the options.

What not to do: don't hide part of your history, don't leave a medicine off the list, and don't keep paying for visit after visit hoping someone will ignore a documented safety concern. That's not access. That's risk.

What happens after you're prescribed Mounjaro?

Answer capsule: Adults start at 2.5 mg once a week. After four weeks, the label moves to 5 mg once a week. If more blood-sugar control is needed, the clinician may raise the dose by 2.5 mg after at least four weeks on the current dose. The adult maximum is 15 mg once weekly. Children age 10 and older have a labeled maximum of 10 mg once weekly.

• Weeks 1–4: 2.5 mg once weekly. This is the starting dose used to begin treatment and lower the chance of stomach side effects during dose escalation.
• After four weeks: 5 mg once weekly. Everything after that depends on your blood sugar, side effects, other medicine, and the prescriber's judgment.
• Do not skip ahead. The label calls for at least four weeks on a dose before another 2.5 mg increase.
• Common side effects can show up during dose increases. Nausea, diarrhea, less appetite, vomiting, constipation, indigestion, and stomach pain are the most common reactions in the label. In trials, nausea, vomiting, and diarrhea were more common while the dose was being raised and decreased over time for many patients.
• Know when to call. Severe or lasting stomach pain, repeated vomiting, or signs of dehydration need prompt medical advice. A serious allergic reaction or severe low blood sugar can be an emergency. Follow the Medication Guide and seek urgent help when symptoms are severe.
• Single-dose pen or vial storage. Keep it in the refrigerator at 36–46°F, protected from light, and never freeze it. A single-dose pen or vial can be kept at room temperature up to 86°F for up to 21 days. Other devices, including the KwikPen, have their own instructions, so follow the package for the exact product you receive.
• If you miss a dose. The label says to take it within 4 days, or 96 hours, of the missed dose. If more than 4 days have passed, skip it and take the next dose on the regular day. Do not take two doses within 72 hours of each other.
• Refills and prior authorization. LillyDirect's pharmacy partner handles its checkout and refill steps. Insurance authorization length is plan-specific, so save the approval letter and its end date instead of assuming it lasts 6 or 12 months.

What real patients say

These are public reviews of the care experience on Sesame's Mounjaro page. They describe visits and access, not medication results. They are not claims about how well Mounjaro works, and individual experiences vary.

“They helped me get the cheapest prescription I have ever gotten!” — Kevin, review shown on Sesame

“Easy to navigate and fast to get appointments and prescriptions.” — Eric, review shown on Sesame

Another reviewer said the paired doctor was kind, empathetic, explained the visit clearly, and prescribed the care she needed. These are provider-selected reviews, not an independent sample.

And one from the public record, because it says the quiet part out loud. In appeal 2405606, a man with type 2 diabetes had repeated Mounjaro requests denied. At the hearing, he compared his experience with a friend who had been approved quickly and asked why he was being given such a hard time. He also talked about being a father and wanting to live longer.

His type 2 diabetes diagnosis was not the missing fact. The file did not show the dates, duration, and combination details needed under that plan's earlier-drug rule.

In the other three decisions, the problem was different. Two requests ran into an obesity-drug exclusion. One involved type 1 diabetes, an off-label request, and evidence that did not meet the payer's rule.

That is the damaging truth: there is no one magic sentence that gets Mounjaro approved. Diagnosis, benefit design, clinical evidence, past-drug records, and dates can each decide the answer. The part you can control before the visit is the quality and honesty of the file you bring.

Frequently asked questions

What is the easiest way to get prescribed Mounjaro?

Start with the clinician who already treats your type 2 diabetes. They usually have the labs and medication history an insurer may ask for. If you do not have one or cannot get in, Eli Lilly's diabetes telehealth directory currently lists HealthTap and Sesame. Lilly posts self-pay visits from $50 to $129 and average first openings within 24 hours. The visit is an evaluation. It does not guarantee a prescription.

Can I get Mounjaro if I'm not diabetic?

A state-authorized prescriber can legally prescribe a drug off-label, but Mounjaro is FDA-approved for type 2 diabetes, not weight loss. Lilly's Mounjaro self-pay offer and both current savings-card tiers require an approved-use prescription that matches the label. If weight loss is your goal, ask whether you meet the FDA label for Zepbound, which contains the same active ingredient.

How much does Mounjaro cost without insurance in 2026?

LillyDirect lists a self-pay price starting at $499 per month for each listed Mounjaro single-dose pen strength from 2.5 mg to 15 mg. A prescription for an approved use is required, and the page says added taxes and fees may apply. The current list price is $1,112.16 for a 28-day supply, but pharmacy cash prices can differ.

Can a telehealth doctor prescribe Mounjaro?

Yes. A clinician authorized to prescribe in your state can prescribe Mounjaro after evaluating you and deciding it is appropriate. Sesame, PlushCare, WeightWatchers Med+, and Noom Med each show a Mounjaro or branded-med path. Eli Lilly separately lists HealthTap for diabetes telehealth. Ro does not currently offer Mounjaro. No platform can promise a prescription before the clinician reviews you.

What A1C do I need for Mounjaro?

There is no minimum A1C number in the FDA-approved Mounjaro indication. A clinician looks at the full medical picture, and each insurance plan can set its own coverage rules. In appeal 2405606, a patient with type 2 diabetes and an A1C of 7.9 was denied because the file did not prove the required past-drug timeline, not because 7.9 was below one national Mounjaro cutoff.

Do I have to try metformin first?

Not under one universal national rule. Some insurance plans use step therapy and may require metformin or another preferred medicine before Mounjaro. Other plans use different rules. One Massachusetts Medicaid decision required at least 90 days of metformin with either Trulicity or Victoza inside a four-month period, with dates. Ask your plan for its current written rule.

Why was my Mounjaro prior authorization denied?

Read the written reason. Common categories include an indication that does not match the plan rule, a benefit exclusion, step therapy, a formulary rule, a safety concern, or missing records. The four public decisions on this page included two obesity-benefit exclusions, one type 1/off-label evidence problem, and one missing-timeline problem. Ask whether the next step is a corrected PA, an exception, or an appeal.

Does Medicare cover Mounjaro?

It depends on your Part D plan's formulary and rules. Mounjaro's labeled use is type 2 diabetes, and a plan may require prior authorization or step therapy. The manufacturer savings card cannot be used with Medicare. If you pay cash through LillyDirect, its terms say the payment does not count toward Medicare Part D TrOOP. The 2026 Part D annual out-of-pocket threshold for covered drugs is $2,100.

Can I get Mounjaro through the Medicare GLP-1 Bridge?

No. The Medicare GLP-1 Bridge started July 1, 2026 and currently covers Foundayo tablets, Wegovy injection or tablets, and the Zepbound KwikPen for eligible people. It does not list Mounjaro. CMS says a person with type 2 diabetes is ineligible for the Bridge even when the current Part D plan does not cover a GLP-1 for that condition. Mounjaro follows the person's normal Part D formulary, exception, and appeal rules.

Can I get Mounjaro the same day?

A same-day appointment and same-day prescription can happen when a clinician has enough information and decides Mounjaro is appropriate. That does not mean you will have the medicine the same day. Insurance review, pharmacy stock, LillyDirect onboarding, and shipping can add time.

Is Mounjaro cheaper than Zepbound?

Not through the current LillyDirect self-pay offers at the lowest doses. Mounjaro starts at $499 per month. Zepbound is $299 at 2.5 mg and $399 at 5 mg. Zepbound's $449 price for 7.5–15 mg requires a refill within 45 days. Miss that window and Lilly lists $499 at 7.5 mg or $699 at 10, 12.5, and 15 mg. Compare the exact dose and terms, not just the headline.

Can my regular doctor prescribe Mounjaro?

Yes. You do not need an endocrinologist just because the medicine is Mounjaro. A clinician who is authorized to prescribe in your state can write it if they decide it is appropriate. If your regular doctor already manages your diabetes, that is often the easiest place to start because the records are already there.

Do I need bloodwork before getting Mounjaro?

It depends on your health history, the clinician, and what is already in your chart. A prescriber may want a recent A1C, kidney information, or other labs. Sesame says labs may be ordered when needed. PlushCare says labs are often required and a second visit may be needed. Ask whether recent labs from your current doctor can be used before paying for new ones.

Is compounded tirzepatide the same as Mounjaro?

No. Mounjaro is the FDA-approved product made by Eli Lilly. Compounded tirzepatide is made by a compounding pharmacy and is not FDA-approved. The broad shortage-based copying window ended in 2025. A narrow patient-specific 503A route may still exist when the law's conditions are met and a prescriber documents a significant difference for that identified patient.

Can I buy Mounjaro online without a prescription?

No lawful U.S. Mounjaro route skips the prescription. FDA warns that illegally sold online tirzepatide may be counterfeit, may contain the wrong amount or no active ingredient, or may contain harmful ingredients. Use a state-authorized prescriber and a state-licensed pharmacy.

What if my pharmacy is out of stock?

Ask when it expects the exact strength, whether it can order it, and whether another in-network location has it. You can ask the prescriber's office to transfer the prescription when allowed. The national tirzepatide shortage is resolved, but FDA says local supply disruptions can still happen.

Does LillyDirect prescribe Mounjaro?

No. LillyDirect is a pharmacy route, not a prescriber. A clinician must first evaluate you and send a valid prescription. Lilly tells prescribers to route it to LillyDirect Pharmacy using NPI 1912889320 and NCPDP 1574056.

Is the $499 Mounjaro price guaranteed for every person?

No. Lilly says starting at $499/month for the six listed single-dose pen strengths. The offer has approved-use, age, residency, and self-pay terms, and added taxes and fees may apply. The separate non-covered commercial savings-card tier says as low as $499 and has its own eligibility rules.

How we researched this

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

For this page, we read the current FDA-approved prescribing information for Mounjaro and Zepbound, Lilly's Mounjaro Savings Card terms, LillyDirect Mounjaro purchase terms, Lilly's diabetes telehealth directory, Lilly's current price pages, FDA's current compounding policy and GLP-1 safety warnings, CMS's 2026 Part D rules, Medicare's current GLP-1 Bridge page, and four published Mounjaro appeal decisions from the Massachusetts Board of Hearings.

We then opened each named telehealth platform's own current page. We label those details provider-stated because a company page can tell us its posted price and process, but it cannot prove what every reader will experience.

We do earn commissions when readers start care through certain links, and that's disclosed at the top of this page. Where a provider we earn nothing from may be the better fit — HealthTap for some insured readers — we say so.

Method limits: We did not enroll in each service, submit an insurance claim, test fulfillment time in every ZIP code, or review every plan. Prices, formulary rules, card terms, and availability can change. The verification date appears next to the claims most likely to change.

Corrections log

Still not sure which path is yours?

You've got the diagnosis rule, the four doors, the $499 manufacturer reference, and the checklist that can keep a blank line from sinking a request. If you know which door is yours, take the next step.

If you don't, that's normal. It takes about two minutes to sort it out.

Still not sure which GLP-1 path is right for you? Take the free Find My GLP-1 Path quiz.

No email needed. It asks up to nine short questions about your goal, insurance, state, budget, and treatment preference. It gives you a route to review. It does not prescribe medicine or guarantee coverage.

Important safety information

Mounjaro (tirzepatide) is an injectable prescription medicine used with diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. It is not known if Mounjaro is safe and effective in children under 10. Mounjaro is not FDA-approved for type 1 diabetes or for weight loss.

Boxed warning: risk of thyroid C-cell tumors. Tirzepatide caused thyroid C-cell tumors in rats. It is not known whether Mounjaro causes these tumors, including medullary thyroid carcinoma, in people. Do not use Mounjaro if you or a family member has had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious allergic reaction to tirzepatide or any Mounjaro ingredient.

Mounjaro may cause serious side effects, including pancreatitis, low blood sugar when used with insulin or a sulfonylurea, serious allergic reactions, kidney injury from dehydration, severe stomach problems, diabetic retinopathy complications, gallbladder problems, and a risk of food or liquid entering the lungs during surgery or procedures that use anesthesia or deep sedation. The most common side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Tell your clinician about all medical conditions and all medicines you take, including if you are pregnant, planning pregnancy, breastfeeding, using insulin or a sulfonylurea, or taking oral birth-control pills. The label says oral hormonal contraception may work less well for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase; ask about a non-oral or barrier method during those windows.

This is not a complete list of risks. Read the full prescribing information and the Medication Guide that comes with the medicine. This page is for information only and is not medical advice.

Sources

Primary and official sources

• Eli Lilly and Company — Mounjaro U.S. Prescribing Information, revised 04/2026.
• Eli Lilly and Company — Mounjaro FAQ and current $1,112.16 list price.
• Eli Lilly and Company — Mounjaro Savings & Coverage terms, CMAT-31122 08/2026.
• Eli Lilly and Company — LillyDirect Mounjaro, CMAT-26577 07/2026.
• Eli Lilly and Company — LillyDirect Mounjaro Self Pay Purchase Offer Terms, CMAT-26577 05/2026.
• Eli Lilly and Company — Mounjaro pricing information, CMAT-08352 06/2026.
• Eli Lilly and Company — Independent telehealth for diabetes, CMAT-28219 05/2026.
• Eli Lilly and Company — Zepbound U.S. Prescribing Information.
• Eli Lilly and Company — LillyDirect Zepbound.
• Eli Lilly and Company — Lilly and U.S. government agreement, November 6, 2025.
• Eli Lilly and Company — Open letter on tirzepatide compounded with vitamin B12, March 12, 2026.
• Alliance for Pharmacy Compounding — Response to Lilly's tirzepatide-plus-B12 statement, March 12, 2026.
• U.S. Food and Drug Administration — FDA policies for GLP-1 compounders.
• U.S. Food and Drug Administration — FDA concerns with unapproved GLP-1 drugs.
• U.S. Food and Drug Administration — Compounding and the FDA: Questions and Answers.
• U.S. Food and Drug Administration — Locate a state-licensed online pharmacy.
• Massachusetts Executive Office of Health and Human Services, Board of Hearings — Appeal 2302617, Appeal 2301838, Appeal 2309642, and Appeal 2405606.
• Centers for Medicare & Medicaid Services — Final CY 2026 Part D Redesign Program Instructions.
• Medicare.gov — Weight-loss drugs and Medicare GLP-1 Bridge.

Provider-stated access and price pages

• Sesame Care Mounjaro.
• Ro Mounjaro availability and Ro pricing.
• PlushCare Mounjaro.
• WeightWatchers Mounjaro and WW Med+ membership cost.
• Noom Med Mounjaro and Noom Med pricing.
• HealthTap diabetes care and pricing, HealthTap membership pricing, and HealthTap insurance support.

Page last verified August 7, 2026 by The RX Index Editorial Team. Next scheduled re-verification: September 7, 2026.